You are viewing the site in preview mode

Skip to main content

Advertisement

Table 2 Patient characteristics of incident GnRH agonist users

From: Gonadotropin-releasing hormone agonist use in men without a cancer registry diagnosis of prostate cancer

Incident GnRH agonist users
Characteristics Strata SEER groupa Non-SEER groupb Proportion not in SEER group  
   n nc % p-valued
Total   17424 1700 8.9  
Year of diagnosis 1993 2008 190 8.6 0.26
  1994 1983 269 11.9  
  1995 2034 178 8.0  
  1996 2330 265 10.2  
  1997 2750 215 7.3  
  1998 2964 260 8.1  
  1999 3355 323 8.8  
Age at diagnosis (years) 67 – 74 8209 653 7.4 0.11
  ≥75 9215 1047 10.2  
Race White 14484 1395 8.8 0.70
  Black 1626 199 10.9  
  Other/Unknown 1314 106 7.5  
Region Northeast 2570 265 9.3 0.15
  Midwest 5597 351 5.9  
  South 1331 156 10.5  
  West 7926 928 10.5  
Zip education < 12.5% 4223 294 6.5 0.65
(% adult <12 years education) ≥12.5% 12090 966 7.4  
Comorbidity Index 0 12604 1045 7.7 0.03
  ≥1 4820 655 12.0  
  1. aDiagnosis of prostate cancer registered in SEER
  2. bDiagnosis of prostate cancer from Medicare claims, but not in SEER, and excluding men who may have had a delay in reporting, moved out of the SEER area at the time of diagnosis or failed the SEER to Medicare linkage
  3. cSample size inflated by a factor of 20 to account for 5% sample and rounded to nearest integer
  4. dChi-square test for comparison of proportions across strata for each characteristic, based on uninflated sample sizes. P-value reported for year of diagnosis is based on test for linear trend
  5. GnRH; Gonadotropin-releasing hormone
  6. SEER; Surveillance, Epidemiology and End-Results